PT/INR Should NOT Be Used to Monitor Dabigatran
PT and INR are unsuitable for assessing the anticoagulant activity of dabigatran and should not be used for monitoring patients on this medication. 1, 2
Why PT/INR Fails for Dabigatran
Dabigatran has minimal effect on PT and INR at clinically relevant plasma concentrations, making these tests fundamentally inappropriate for assessing dabigatran's anticoagulant effect. 1 The FDA drug label explicitly states that "INR is relatively insensitive to the exposure to dabigatran and cannot be interpreted the same way as used for warfarin monitoring." 2
Critical Pitfalls to Avoid
Point-of-care INR devices are particularly problematic and produce falsely elevated INR values in dabigatran-treated patients—up to 2-4 fold higher than laboratory measurements. 3, 4 At therapeutic dabigatran concentrations (60-275 ng/mL), point-of-care INR values ranged from 1.7 to 4.0 versus laboratory values of only 1.1 to 1.5. 3
Do not use INR to guide clinical decisions about bleeding risk, surgical timing, or dose adjustments in dabigatran patients, as the values do not accurately reflect anticoagulant activity. 1, 5, 6
Converting PT to INR does not correct for variability and actually increases variability when DOACs are present, since the INR system was designed specifically for vitamin K antagonists. 1
What Tests Should Be Used Instead
For Qualitative Assessment (Presence/Absence of Drug)
aPTT provides a qualitative assessment of dabigatran level and anticoagulant activity, though the relationship is curvilinear and becomes less sensitive at higher concentrations (≥200 ng/mL). 1, 2
Thrombin time (TT) is extremely sensitive to dabigatran presence—a normal TT effectively excludes even very low levels of dabigatran. 1, 7 However, TT is too sensitive for quantifying therapeutic or supratherapeutic levels. 5, 7
For Quantitative Assessment (Drug Concentration)
The European Heart Rhythm Association recommends using plasma concentrations rather than coagulation test results to quantitatively assess dabigatran. 1
Diluted thrombin time (dTT) displays a direct linear relationship with dabigatran concentration and is suitable for quantitative assessment. 1, 7
Ecarin chromogenic assay (ECA) also shows a direct linear relationship with dabigatran concentration. 1
Ecarin clotting time (ECT) is a more specific measure of dabigatran effect than aPTT. 2 In the RE-LY trial, median trough ECT in patients receiving 150 mg was 63 seconds (10th-90th percentile: 44-103 seconds). 2
Emergency/Bleeding Situations
When a patient on dabigatran presents with bleeding or requires urgent surgery:
Measure aPTT and thrombin time as rapidly available screening tests to assess recent drug exposure. 1, 8, 6
Consider specific dabigatran assays (dTT or ECA) if available within an acceptable timeframe for quantitative drug level assessment. 1, 8
Do not measure PT/INR, as these will not provide useful information for clinical decision-making. 1, 5, 6
Know the timing of the last dose relative to blood sampling, as dabigatran reaches maximum plasma concentration 1-3 hours post-administration. 1